Advertisement

Topics

Gilead Sciences Company Profile

04:02 EST 23rd November 2017 | BioPortfolio

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions forpatients and the people who care for them. The Company discovers, develops and commercializes proprietary therapeutics for important viral diseases, including the currently marketed product VISTIDE-Registered Trademark- (cidofovir injection) for the treatment of cytomegalovirus ("CMV") retinitis, a sight-threatening viral infection in patients with acquired immune deficiency syndrome ("AIDS"). In addition, the Company is developing products to treat diseases caused by human immunodeficiency virus ("HIV"), hepatitis B virus ("HBV") and influenza virus.

Location

333 Lakeside Drive
Foster City
CA
94404
United States of America

Contact

Phone: 650 574 3000
Fax: 650 578 9264
Email: public_affairs@gilead.com


News Articles [808 Associated News Articles listed on BioPortfolio]

Gilead Sciences to acquire Kite Pharma for $11.9B

Gilead Sciences and Kite Pharma announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which v...

Gilead Sciences Announces Third Quarter 2017 Dividend

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.52 per share of common stock for the third quarter o...

STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences

A new HIV pill from Gilead Sciences suppressed the virus in newly diagnosed patients, a late-stage study showed. The data are a big boost to Gilead.

Gilead Sciences Announces Fourth Quarter 2017 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.52 per share of common stock for the fourth quarter...

Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6

Friday, September 1st 2017 at 1:00pm UTC Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Ke...

Gilead Sciences: 3-Stufen-Analyse vom 11.07.2017

Die Gilead Sciences-Aktie notiert seit dem letzten Handelstag 0,06% höher. Der aktuelle Kurs beträgt 69,29$. Der Kurs der Gilead Sciences-Aktie änderte sich in der letzten Woche um -1,99% und seit ...

M&As this week: Gilead Sciences, RegenxBio

Gilead Sciences and its subsidiary Dodgers Merger Sub plan to acquire Kite Pharma for $11.9bn.

Aktuelles zur Kursrallye bei Gilead Sciences-Aktie - Aktiennews

Bad Marienberg - +++ Aktuelles zur Kursrallye bei Gilead Sciences-Aktie +++ Aktiennews Der Aktienkurs des US-Biotechkonzerns Gilead Sciences Inc. (ISIN: US3755581036, WKN 885823, Ticker-Symbol: GIS...

Drugs and Medications [24 Associated Drugs and Medications listed on BioPortfolio]

Primer [Derma Sciences Canada, Inc.]

Drug Facts

Primer [Derma Sciences Canada, Inc.]

Drug Facts

Mysotrol no rinse antiseptic hand cleanser [Derma Sciences]

Drug Facts

Primaderm anti-dandruff [Derma Sciences]

Drug Facts

Hepsera [Gilead Sciences, Inc.]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

PubMed Articles [607 Associated PubMed Articles listed on BioPortfolio]

The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.

Georgia, a country in the Caucasus region of Eurasia, has a high prevalence of hepatitis C virus (HCV) infection. In April 2015, with technical assistance from CDC, Georgia embarked on the world's fir...

Corrigendum.

Erratum.

Sex and aging.

Corrigendum.

Clinical Trials [168 Associated Clinical Trials listed on BioPortfolio]

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus S...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir and Ledipasvir from M...

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Magicbuvir 400 m...

A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Elbanovir 400 mg...

Companies [1026 Associated Companies listed on BioPortfolio]

Gilead Sciences Canada, Inc.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to...

Gilead Sciences, Inc. and Boehringer Ingelheim

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to adva...

Gilead Sciences, Inc.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to adva...

Gilead Sciences

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions forpatients and the people who care for them. The Company discovers, develops and commerci...

Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....

More Information about "Gilead Sciences" on BioPortfolio

We have published hundreds of Gilead Sciences news stories on BioPortfolio along with dozens of Gilead Sciences Clinical Trials and PubMed Articles about Gilead Sciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gilead Sciences Companies in our database. You can also find out about relevant Gilead Sciences Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...


Corporate Database Quicklinks



Searches Linking to this Company Record